Alpha Tau Receives FDA Approval to Expand Alpha DaRT Pancreatic Cancer Trial with Gemcitabine-Abraxane Combination

Key Takeaways

• FDA approves IDE supplement expanding Alpha DaRT IMPACT trial to include gemcitabine with Abraxane chemotherapy regimen
• Trial enrollment increases from 30 to 40 patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma
• Expansion covers both primary standard-of-care chemotherapy options for pancreatic cancer alongside existing mFOLFIRINOX arm

---

Alpha Tau Medical Ltd. announced FDA approval of an Investigational Device Exemption (IDE) supplement to expand its Alpha DaRT® IMPACT clinical trial, adding patients with pancreatic cancer receiving gemcitabine combined with Abraxane® (nab-paclitaxel) chemotherapy.

Trial Expansion Details

The IDE supplement represents a significant milestone for Alpha Tau’s Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. The expansion allows the company to evaluate its radioactive seed therapy alongside both primary standard-of-care chemotherapy regimens for pancreatic cancer patients.

The IMPACT trial now encompasses patients receiving either mFOLFIRINOX or the gemcitabine-Abraxane combination, reflecting real-world treatment patterns for pancreatic adenocarcinoma. This dual-arm approach provides broader applicability for the investigational treatment.

Patient Population and Study Design

The expanded trial will enroll patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. Total enrollment increases from 30 to 40 patients, allowing for more robust data collection across both chemotherapy regimens.

Pancreatic cancer remains one of the most challenging malignancies, with limited treatment options and poor prognosis. The five-year survival rate for pancreatic cancer is approximately 11%, highlighting the urgent need for innovative therapeutic approaches.

Alpha DaRT Technology

Alpha DaRT utilizes radioactive seeds containing radium-224, which decay to release alpha particles with high linear energy transfer. This targeted radiation approach aims to destroy cancer cells while minimizing damage to surrounding healthy tissue.

The technology represents Alpha Tau’s broader strategy to address cancers with significant unmet medical needs. By combining Alpha DaRT with established chemotherapy regimens, researchers hope to improve outcomes for patients facing limited therapeutic options.

Market Implications

The FDA’s approval of this trial expansion demonstrates regulatory confidence in Alpha DaRT’s safety profile and potential efficacy. For Alpha Tau, the expanded trial provides crucial data to support future regulatory submissions and potential commercialization efforts.

The pancreatic cancer therapeutics market continues growing as pharmaceutical companies seek breakthrough treatments for this devastating disease. Alpha DaRT’s unique mechanism of action positions it as a potentially differentiated option in the competitive oncology landscape.

---

Frequently Asked Questions

What does this FDA approval mean for pancreatic cancer patients?

The FDA approval allows more pancreatic cancer patients to potentially access Alpha DaRT therapy through the clinical trial, specifically those receiving gemcitabine-Abraxane chemotherapy, expanding treatment options within the study.

When will Alpha DaRT be commercially available for pancreatic cancer?

Alpha DaRT is still in clinical trials. The IMPACT study is a pilot trial that will provide data for future larger studies. Commercial availability depends on successful completion of clinical development and FDA approval.

How does Alpha DaRT differ from traditional radiation therapy?

Alpha DaRT uses radioactive seeds that emit alpha particles directly within tumors, providing targeted radiation with high energy transfer while potentially reducing damage to surrounding healthy tissue compared to external beam radiation.